Protara Therapeutics, Inc. TARA shares are down during Tuesday’s premarket session following the release of updated interim ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countriesDublin-based subsidiary to support ImmunityBio’s distribution and ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

As of Monday, February 23, ImmunityBio, Inc.’s IBRX share price has surged by 20.31%, which has investors questioning if this ...

As of Tuesday, February 24, Burning Rock Biotech Limited’s BNR share price has dipped by 6.28%, which has investors questioning if this is right time to buy.

A MUM who worried about her tummy pain but was dismissed by doctors for seven years needed six of her organs removed.

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...